|
HY-13422-1mL
|
MedChemexpress LLC
|
Zatebradine (hydrochloride) [CAS 91940-87-3] (10mM in DMSO)
|
|
COVID-19-immunoregulation
|
|
|
HY-13422A-10mg
|
MedChemexpress LLC
|
Zatebradine [CAS 85175-67-3]
|
|
COVID-19-immunoregulation
|
|
|
HY-13422A-5mg
|
MedChemexpress LLC
|
Zatebradine [CAS 85175-67-3]
|
|
COVID-19-immunoregulation
|
|
|
HY-13422A-50mg
|
MedChemexpress LLC
|
Zatebradine [CAS 85175-67-3]
|
|
COVID-19-immunoregulation
|
|
|
HY-13422A-1mL
|
MedChemexpress LLC
|
Zatebradine [CAS 85175-67-3] (10mM in DMSO)
|
|
COVID-19-immunoregulation
|
|
|
HY-124571-10mg
|
MedChemexpress LLC
|
ZQ-16 [CAS 376616-73-8]
|
|
|
|
|
HY-124571-100mg
|
MedChemexpress LLC
|
ZQ-16 [CAS 376616-73-8]
|
|
|
|
|
HY-124571-25mg
|
MedChemexpress LLC
|
ZQ-16 [CAS 376616-73-8]
|
|
|
|
|
HY-124571-5mg
|
MedChemexpress LLC
|
ZQ-16 [CAS 376616-73-8]
|
|
|
|
|
HY-124571-50mg
|
MedChemexpress LLC
|
ZQ-16 [CAS 376616-73-8]
|
|
|
|
|
HY-124571-1mL
|
MedChemexpress LLC
|
ZQ-16 [CAS 376616-73-8] (10mM in DMSO)
|
|
|
|
|
HY-132300A-10mg
|
MedChemexpress LLC
|
ZW4864 (free base) [CAS 2632259-92-6]
|
|
Cancer-programmed cell death
|
|
|
HY-132300A-100mg
|
MedChemexpress LLC
|
ZW4864 (free base) [CAS 2632259-92-6]
|
|
Cancer-programmed cell death
|
|
|
HY-132300A-25mg
|
MedChemexpress LLC
|
ZW4864 (free base) [CAS 2632259-92-6]
|
|
Cancer-programmed cell death
|
|
|
HY-132300A-5mg
|
MedChemexpress LLC
|
ZW4864 (free base) [CAS 2632259-92-6]
|
|
Cancer-programmed cell death
|
|
|
HY-132300A-50mg
|
MedChemexpress LLC
|
ZW4864 (free base) [CAS 2632259-92-6]
|
|
Cancer-programmed cell death
|
|
|
HY-132300A-1mL
|
MedChemexpress LLC
|
ZW4864 (free base) [CAS 2632259-92-6] (10mM in DMSO)
|
|
Cancer-programmed cell death
|
|
